Loading clinical trials...
Loading clinical trials...
Phase II, Open-Label, Prospective Study of T Cell Receptor Alpha/Beta Depletion (A/B TCD) Peripheral Blood Stem Cell (PBSC) Transplantation for Children and Adults With Hematological Malignancies
Conditions
Interventions
Fludarabine
Busulfan
+6 more
Locations
1
United States
University of Minnesota Masonic Cancer Center
Minneapolis, Minnesota, United States
Start Date
May 11, 2023
Primary Completion Date
November 30, 2027
Completion Date
November 30, 2030
Last Updated
April 6, 2026
NCT05417971
NCT07295951
NCT07371403
NCT05529069
NCT04065399
NCT06859424
Lead Sponsor
Masonic Cancer Center, University of Minnesota
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions